Knockout identification of target-specific sites in peptides

Details Knockout identification of target-specific sites in peptides Knockout identification of target-specific sites in peptides

2008-04-01

2008-04-01

Kam, Chih-Min (Department: 1656)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S300000, C530S326000, C530S327000, C530S328000, C530S329000, C530S330000, C530S331000, C435S007100

Reexamination Certificate

active

07351690

ABSTRACT:
The invention provides methods for identification and determination of target-specific sites in peptides and proteins, including a method for determining the primary sequence of a secondary structure within a known parent polypeptide that binds to the target of interest. In one embodiment of the invention, a residue or mimetic containing a nitrogen atom and a sulfur atom available for binding to a metal ion is serially substituted for single residues in or inserted between adjacent residues in a known primary sequence of a peptide or protein. The resulting sequence is complexed with a metal ion thereby forming a metallopeptide. The resulting metallopeptides are then used in binding or functional assays related to the target of interest, and the metallopeptide(s) which result in significant or substantially decreased or changed binding or functionality are determined to identify the primary sequence involved in such binding or functionality.

REFERENCES:
patent: 5834250 (1998-11-01), Wells et al.
patent: 5891418 (1999-04-01), Sharma
patent: 6027711 (2000-02-01), Sharma
patent: 6083758 (2000-07-01), Imperiali et al.
patent: 6084066 (2000-07-01), Evans et al.
patent: 6278794 (2001-08-01), Parekh et al.
patent: 6331285 (2001-12-01), Sharma
patent: 2001/0000807 (2001-05-01), Freire et al.
patent: WO 96/40293 (1996-12-01), None
patent: WO 00/23564 (2000-04-01), None
patent: WO 00/36136 (2000-06-01), None
patent: WO 00/57309 (2000-09-01), None
patent: WO 01/35316 (2001-05-01), None
patent: WO 01/50355 (2001-07-01), None
patent: WO 01/59066 (2001-08-01), None
patent: WO 02/064734 (2002-08-01), None
Chan, W. Y., et al., “Discovery and Design of Novel and Selective Vasopressin and Oxytocin Agonists and Antagonists: The Role of Bioassays”,Experimental Physiology, vol. 85 Suppplement 1, Abstract only supplied,(Mar. 2000),7S-18S.
Deschodt-Lanckman, Monique, et al., “In Vitro Action of Bombesin and Bombesin-Like Peptides on Amylase Secretion, Calcium Efflux, and Adenylate Cyclase Activity in Rat Pancreas”,Journal of Clinical Investigationvol. 58, (Oct. 1976), 891-898.
Grant, Gregory A., “Synthetic Peptides. A User's Guide”,W.H. Freeman and Co., New York 1992, 11-14.
Hampton, Lori L., et al., “Loss of Bombesin-Induced Feeding Suppression in Gastrin-Releasing Peptide receptor-Deficient Mice”,Proc. Natl. Acad. Sci. USA, vol. 95, (Mar. 1998),3188-3192.
Hruby, V J., “Emerging Approaches in the Molecular Design of Receptor-Selective Peptide Ligands: Conformational, Topographical and Dynamic Considerations”,Biochemical Journal, (1990) 268, 249-262.
Leban, Johann J., et al., “Development of Potent Gastrin-Releasing Peptide Antagonists Having a D-Pro-PSI(CH2NH)-Phe-NH2 C Terminus”,Proc. Natl. Acad. Sci. USA, vol. 90, (Mar. 1993),1922-1926.
Maccoll, R. , “Interrelationships among biological active, disulfide bonds, second structure, and themetal binding of a chemically synthesized 34-aminio acid peptide derived from alpha-fetoprotein”,Biochimica Et Biophysic ACTA-General Subjects; vol. 1528, No. 2-3, (Oct. 3, 2001), 127-134.
Moody, Terry W., et al., “Bombesin: Specific Binding to Rat Brain Membranes”,Proc. Natl. Acad. Sci. USA, vol. 75, No. 11, (Nov. 1978),5372-5376.
Simmonds, R. G., et al., “Synthesis of Disulfide-Bridged Fragments of Omega-Conotoxins GVIA and MVIIA. Use of Npys as a Protecting/Activating Group for Cysteine in Fmoc Syntheses”,Int J Pept Protein Res.vol.43(4), Abstract only supplied,(Apr. 1994),363-366.
Soto, Claudio, ““beta”-Sheet Breaker Peptides Inhibit Fobrillogenesis in a Rat Brain Model of Amyloidosis of Amyloidosis: Implications for Alzheimer's Therapy”,Nature Medicine; vol. 4, No. 7, (Jul. 1998),822-826.
Soto, Claudio, “Alzheimer's and Prion Diseases as Disorders of Protein Conformation: Implications for the Design of Novel Therapeutic Approaches”,J Mol Medvol. 77, (1999),412-418.
Soto, Claudio , “Plaque Busters: Strategies to Inhibit Amyloid Formation in Alzheimer's Disease”,Molecular Medicine Today, vol. 5, (Aug. 1999),343-350.
Soto, Clauadio, “Reversion of Prion Protein Conformational Changes by Synthetic”,The Lancet, vol. 355, (Jan. 5, 2000),192-197.
Toniolo, C. , “Conformationally Restricted Peptides Through Short-Range Cyclizations”,Int J Peptide Protein Resvol. 35, (1990),287-300.
Yamada, Kazuyuki , et al., “Bombesin-Like Peptides: Studies on Food Intake and Social Behaviour with Receptor Knock-Out Mice”,The Finnish Medical Society Duodecim, vol. 32, (Ann. Med 2000),519-529.

Affiliated with

Also associated with

Rating

Knockout identification of target-specific sites in peptides does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Knockout identification of target-specific sites in peptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Knockout identification of target-specific sites in peptides will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2798622